Sofosbuvir-induced erythrodermia pityriasis rubra pilaris-like drug eruption

Evelyn J. Cheung; Jaroslaw J. Jedrych; Joseph C. English

Sofosbuvir-induced erythrodermia pityriasis rubra pilaris-like drug eruption

Evelyn J. Cheung, Jaroslaw J. Jedrych, Joseph C. English

Research output: Contribution to journal › Article › peer-review

Abstract

Until 2011, the standard-of-care therapy for patients with hepatitis C consisted of interferon and ribavirin. The recent advent of new targeted therapies against this virus has provided more options of treatment for infected patients. Sofosbuvir, a nucleotide inhibitor of hepatitis C virus (HCV) RNA polymerase, was recently approved by the US Food and Drug Administration in 2013. Various Phase 3 trials with sofosbuvir combination therapy have reported an incidence of rash between 7% and 18%. We here describe a case of sofosbuvir-induced erythrodermic pityriasis rubra pilaris-like drug eruption.

Original language	English (US)
Pages (from-to)	1161-1162
Number of pages	2
Journal	Journal of Drugs in Dermatology
Volume	14
Issue number	10
State	Published - Jan 1 2015
Externally published	Yes

ASJC Scopus subject areas

Dermatology

Cite this

@article{51bbfd114c8045b0b061151f95e26a96,

title = "Sofosbuvir-induced erythrodermia pityriasis rubra pilaris-like drug eruption",

abstract = "Until 2011, the standard-of-care therapy for patients with hepatitis C consisted of interferon and ribavirin. The recent advent of new targeted therapies against this virus has provided more options of treatment for infected patients. Sofosbuvir, a nucleotide inhibitor of hepatitis C virus (HCV) RNA polymerase, was recently approved by the US Food and Drug Administration in 2013. Various Phase 3 trials with sofosbuvir combination therapy have reported an incidence of rash between 7% and 18%. We here describe a case of sofosbuvir-induced erythrodermic pityriasis rubra pilaris-like drug eruption.",

author = "Cheung, {Evelyn J.} and Jedrych, {Jaroslaw J.} and English, {Joseph C.}",

year = "2015",

month = jan,

day = "1",

language = "English (US)",

volume = "14",

pages = "1161--1162",

journal = "Journal of Drugs in Dermatology",

issn = "1545-9616",

publisher = "Journal of Drugs in Dermatology",

number = "10",

}

TY - JOUR

T1 - Sofosbuvir-induced erythrodermia pityriasis rubra pilaris-like drug eruption

AU - Cheung, Evelyn J.

AU - Jedrych, Jaroslaw J.

AU - English, Joseph C.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Until 2011, the standard-of-care therapy for patients with hepatitis C consisted of interferon and ribavirin. The recent advent of new targeted therapies against this virus has provided more options of treatment for infected patients. Sofosbuvir, a nucleotide inhibitor of hepatitis C virus (HCV) RNA polymerase, was recently approved by the US Food and Drug Administration in 2013. Various Phase 3 trials with sofosbuvir combination therapy have reported an incidence of rash between 7% and 18%. We here describe a case of sofosbuvir-induced erythrodermic pityriasis rubra pilaris-like drug eruption.

AB - Until 2011, the standard-of-care therapy for patients with hepatitis C consisted of interferon and ribavirin. The recent advent of new targeted therapies against this virus has provided more options of treatment for infected patients. Sofosbuvir, a nucleotide inhibitor of hepatitis C virus (HCV) RNA polymerase, was recently approved by the US Food and Drug Administration in 2013. Various Phase 3 trials with sofosbuvir combination therapy have reported an incidence of rash between 7% and 18%. We here describe a case of sofosbuvir-induced erythrodermic pityriasis rubra pilaris-like drug eruption.

UR - http://www.scopus.com/inward/record.url?scp=84986598260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84986598260&partnerID=8YFLogxK

M3 - Article

C2 - 26461830

AN - SCOPUS:84986598260

SN - 1545-9616

VL - 14

SP - 1161

EP - 1162

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

IS - 10

ER -

Sofosbuvir-induced erythrodermia pityriasis rubra pilaris-like drug eruption

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this